Focus: Charter Medical is a specialty pharmaceutical company based in Winston-Salem, NC, focused on single-use devices across multiple therapeutic areas including neurology, cardiovascular, oncology, infectious diseases, and metabolic diseases.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Stable — net +4 jobs in 30d
9 added, 5 removed. Backfill posture.
Charter Medical is a revenue-stable but innovation-sparse specialty pharma play best suited for operations, compliance, or commercial roles; significant patent cliff exposure and zero pipeline present elevated restructuring risk for career-focused candidates.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's flagship product representing 71% of revenue; loss of exclusivity approaching signals imminent revenue cliff and business model stress.
Help build intelligence for Charter Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Charter Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only identified patent cliff with specific LOE date; minimal revenue impact but represents residual branded portfolio.
Post-exclusivity generic with $5M Part D spending; part of mature, commoditized portfolio with limited margin expansion potential.
Niche, post-LOE antibiotic with minimal revenue; representative of specialty generics with limited market relevance.
Mature cardiovascular generic with negligible revenue; demonstrates low-margin portfolio composition.
Post-LOE muscle relaxant with minimal revenue; part of low-value specialty generic portfolio.
Legacy tricyclic antidepressant with no recorded Part D spending; legacy portfolio asset with minimal commercial relevance.
Mature antifungal generic with no recorded Part D spending; represents commodity-tier portfolio positioning.
Legacy respiratory generic with no recorded revenue; represents discontinued or minimal-support product line.
Niche antihistamine with no recorded Part D spending; minimal commercial profile within portfolio.
63 discontinued, 50 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+34 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo